EGF-Binding Polypeptides for Selective Growth Factor Retention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional negative pressure wound therapy (NPWT) does not distinguish between beneficial growth factors and detrimental inflammatory cytokines, leading to inefficient wound healing as it removes wound exudate without selectively retaining and sustaining the activity of growth factors like epidermal growth factor (EGF).
Innovation Solution
Development of polypeptides with high affinity for EGF that can bind and sustain its release to promote the proliferation and differentiation of fibroblast and epithelial cells, using sequences at least 70% identical to specific peptide sequences, allowing for targeted delivery and retention of EGF at wound sites.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of substance
If conventional NPWT is applied to remove wound exudate, then fluid removal is achieved, but beneficial growth factors are also removed along with detrimental inflammatory cytokines
Solution Approach 1:
The invention extracts and isolates the beneficial growth factors from the wound exudate by using specific binding agents (such as antibodies or affinity ligands) that selectively bind to growth factors like EGF, PDGF, or VEGF. This allows the separation of beneficial factors from detrimental inflammatory cytokines, preventing the loss of growth factors while still removing harmful substances through negative pressure therapy.
Solution Approach 2:
The invention introduces intermediary substances (binding agents, antibodies, or affinity ligands) that mediate between the wound exudate and the negative pressure therapy system. These intermediaries selectively capture growth factors, allowing them to be retained or controlled during the fluid removal process, thus preventing unwanted loss while maintaining therapeutic effectiveness.
2Productivity
If negative pressure is applied to promote tissue growth, then granulation tissue formation is increased, but growth factor activity is not sustained
Solution Approach 1:
The invention applies preliminary action by pre-loading the wound dressing or therapy system with growth factors or growth factor-binding agents before initiating negative pressure therapy. This ensures that growth factors are present and active from the beginning of treatment, sustaining their activity throughout the tissue growth process rather than being lost or depleted over time.
Solution Approach 2:
The invention ensures continuity of useful action by incorporating mechanisms that maintain growth factor activity throughout the duration of negative pressure therapy. This may involve controlled-release systems, sustained-binding agents, or continuous supplementation of growth factors, ensuring that the beneficial effects are maintained consistently rather than being transient.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polypeptides effectively concentrate EGF at wound sites, enhancing wound healing by promoting cellular proliferation and differentiation, thereby improving tissue growth and repair.
Implementation Method 1
The polypeptides of the present disclosure have high affinity to bind EGF and can retain EGF and sustain its release
Data Source
AI summary
A polypeptide having a sequence at least 70% identical to SEQ ID NO: 1 (YVSPGMKNVNWWSHWWHATD) is provided. The polypeptide includes no more than 100 total amino acid residues.